Colcemide is a microtubule-disrupting ADC payload that interferes with mitosis, leading to tumor cell death. Used as an ADC cytotoxin, it supports precision oncology by enhancing selective delivery and improving therapeutic outcomes in antibody-drug conjugates.
Structure of 477-30-5
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Colcemide, also known by its chemical name demecolcine, is a semi-synthetic analog of colchicine that functions as an ADC cytotoxin. It is utilized as a payload in the development of antibody-drug conjugates for targeted cancer therapy. As a compound with a well-characterized mechanism, Colcemide is integrated into an ADC construct to enable the delivery of its cytotoxic activity directly to tumor cells. This approach leverages its inherent potency while aiming to improve the therapeutic index of the final product. Colcemide's suitability for bioconjugation makes it a component for developing targeted therapeutics.
The cytotoxic activity of Colcemide stems from its mechanism as a tubulin polymerization inhibitor. When this ADC cytotoxin is released inside the target cell, it binds to tubulin heterodimers, preventing their assembly into microtubules. This disruption of microtubule formation leads to the disorganization of the mitotic spindle, resulting in mitotic arrest. By arresting cells in the metaphase of mitosis, Colcemide induces apoptosis, primarily affecting rapidly proliferating cancer cells. This specific antimitotic agent mechanism targets a fundamental process of cell division, which is a key characteristic of many cytotoxic payload classes.
Colcemide is a compound used in bioconjugation research and tumor therapy. Its chemical properties, including its ability to be conjugated to various linkers, support its application in constructing stable and effective antibody-drug conjugates. For researchers and companies focused on developing targeted therapeutics, Colcemide serves as a payload with established cytotoxic activity. The compound’s mechanism of action is a factor in its use for targeting cell proliferation, a hallmark of malignant cells.
What is Colcemide?
Colcemide is a microtubule-disrupting cytotoxin widely used in ADC research. It binds tubulin, preventing microtubule polymerization, which disrupts mitotic spindle formation and halts cell division. This makes it an effective tool for studying targeted cytotoxicity in cancer models.
13/5/2019
Could you explain how Colcemide functions as an ADC payload?
When used in ADCs, Colcemide inhibits microtubule dynamics after cellular uptake, leading to cell cycle arrest and apoptosis. Its high potency allows researchers to design ADCs that target tumor cells specifically, maximizing efficacy while limiting systemic toxicity.
20/5/2018
We are interested in the applications of Colcemide in research. Could you advise?
Colcemide is utilized in preclinical oncology studies to evaluate ADC performance, microtubule-targeted payload delivery, and conjugation stability. It aids in optimizing antibody-linker design and assessing cytotoxic efficiency in vitro and in vivo.
14/12/2019
Could you please let me know what the chemical properties of Colcemide are?
Colcemide is a colchicine derivative that binds to tubulin at the colchicine site, preventing polymerization. Its chemical structure allows for conjugation to antibodies through linkers suitable for ADCs, maintaining cytotoxic activity while ensuring targeted delivery.
7/11/2016
Dear BOC Sciences, how should Colcemide be handled safely in the lab?
Colcemide is highly cytotoxic and requires strict laboratory safety procedures. Protective equipment, fume hoods, and careful waste management are essential to prevent exposure during ADC payload handling, storage, and experimental use.
19/7/2020
— Dr. James Parker, Lead Scientist (USA)
Colcemide from BOC Sciences arrived with high purity and enabled smooth ADC conjugation.
14/12/2019
— Dr. Anthony White, Laboratory Director (UK)
Colcemide from BOC Sciences was delivered in excellent condition, with purity levels that matched our stringent requirements.
19/7/2020
— Ms. Eva Schneider, Biomedical Scientist (Germany)
Our experiments required Colcemide for cytotoxicity studies, and the results were reproducible thanks to its consistent quality.
7/11/2016
— Mr. Lucas Martin, Senior Research Chemist (France)
The compound came with detailed COA and NMR profiles, making Colcemide easy to integrate into our workflows.
13/5/2019
— Dr. Catherine Lewis, Oncology Researcher (USA)
Colcemide from BOC Sciences displayed reliable activity in cell cycle assays, reinforcing our trust in their product portfolio.
— Dr. Tomasz Nowak, Pharmaceutical Scientist (Poland)
The quick turnaround time for Colcemide ensured we kept our project timelines on track. Great supplier experience overall.
20/5/2018
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.